Evidence map›Paper›PMID 29458736›Full record

ReviewHematology/oncology clinics of North America2018

Emerging Therapies.

Amaliris Guerra, Khaled M Musallam, Ali T Taher, Stefano Rivella

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Splenectomy for people with thalassaemia major or intermedia.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Amaliris GuerraDepartment of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia (CHOP), Philadelphia, PA, USA.
Khaled M MusallamInternational Network of Hematology, 31-33 High Holborn, London WC1V 6AX, UK.
Ali T TaherDepartment of Internal Medicine, American University of Beirut Medical Center, PO Box: 11-0236, Cairo Street, Hamra, Raid E Solh, Beirut 1107 2020, Lebanon.
Stefano RivellaDepartment of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia (CHOP), Philadelphia, PA, USA; Cell and Molecular Biology Graduate Group (CAMB), University of Pennsylvania, 421 Curie Boulevard/6064 160 Biomedical Research Building (BRB) 2/3, Philadelphia, PA 19104-6064, USA. Electronic address: rivellas@email.chop.edu.
American University of Beirut Medical Center · LBChildren's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

Regulatory Role of Transferrin in Erythropoiesis and Iron MetabolismR01DK095112 · NIDDK · SAINT LOUIS UNIVERSITY · PI Robert E Fleming, Yelena Ginzburg · 2012 to 2026
$5.4M
Hepcidin therapy for iron overload and hematologic disordersR01DK090554 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI RIVELLA, STEFANO · 2010 to 2021
$5.2M
NIDDK NIH HHS R01 DK090554NIDDK NIH HHS R01 DK095112
6 · The paper itself

Abstract

At present, the only definitive cure for β-thalassemia is a bone marrow transplant (BMT); however, HLA-blood-matched donors are scarcely available. Current therapies undergoing clinical investigation with most potential for therapeutic benefit are the β-globin gene transfer of patient-specific hematopoietic stem cells followed by autologous BMT. Other emerging therapies deliver exogenous regulators of several key modulators of erythropoiesis or iron homeostasis. This review focuses on current approaches for the treatment of hemoglobinopathies caused by disruptions of β-globin.

Indexed as

Animalsbeta-Globinsbeta-ThalassemiaClinical Trials as TopicCombined Modality TherapyDisease ManagementDrug DiscoveryDrug Evaluation, PreclinicalErythropoiesisHumansbeta-GlobinsGene transferHemichromesNew therapiesTrap ligandsβ-Globinβ-Thalassemia

Identifiers

PMID29458736
PMCPMC5823282
OpenAlexW4235033170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.